Brain Cancer Archives

Oncotarget News

Zika Virus as a Treatment for Brain Cancer: A Systematic Review

October 9, 2024

Despite limited human evidence, it shows potential benefits.”BUFFALO, NY- October 9, 2024 – A new review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Zika virus and... read more

Oncotarget

Next-Gen Vaccines Offer New Hope Against Glioblastoma

September 9, 2024

Vaccines have been considered a promising approach for GBM for many years.”BUFFALO, NY- September 9, 2024 – A new editorial was published in Oncotarget's Volume 15 on August 5, 2024,... read more

Gold nanostars amplify brain-tumor selective laser interstitial thermal therapy.

Oncotarget

Leveraging Gold Nanostars for Precision Laser Interstitial Thermal Therapy

June 24, 2024

Gold nanostars amplify brain-tumor selective laser interstitial thermal therapy.”BUFFALO, NY- June 24, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 14, 2024, entitled, “Leveraging... read more

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

Oncotarget

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.”BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,... read more

Oncotarget

ATR Inhibition Using Gartisertib in Patient-derived Glioblastoma Cell Lines

January 17, 2024

this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.”BUFFALO, NY- January 17, 2024 – A new research paper was published in Oncotarget's Volume 15 on January... read more

Oncotarget

GBP3-STING Interaction in Glioblastoma Coordinates Poor Response to Temozolomide

October 17, 2023

The paper revealed a critical role of GBP3 involving multiple [temozolomide] resistance mechanisms.”BUFFALO, NY- October 17, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on May... read more

Figure 1: (A) Canonical STAT3 activation pathway. (B) WP1066 and TTI-101, examples of small molecule STAT3 inhibitors that are cell penetrant.

Oncotarget

STAT3 as a Target in H3K27M-mutant DMGs

October 9, 2023

Children diagnosed with these tumors have [...] a median survival of approximately 12 months.” BUFFALO, NY- October 9, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on... read more

Oncotarget

Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer

September 13, 2023

With these new drugs now available in clinical practice, we expect HER2+/HER2-low BC patients with BMs to live longer and to live better.”BUFFALO, NY- September 13, 2023 – A... read more

Figure 2: Mechanism of radiation resistance in H3K27me3-deficient medulloblastoma.

Oncotarget

Epigenetically Guided Cancer Therapy: Targeting H3K27me3 Loss in Pediatric Brain Tumors

August 2, 2023

our discovery of H3K27me3 as an epigenetic marker of radiation resistance in medulloblastoma has a potential to open new therapeutic avenues [...]”BUFFALO, NY- August 2, 2023 – A new editorial paper... read more

Figure 1: Comparison of progression-free survival (A) and overall survival (B) between children (

Oncotarget

Oncotarget | WNT-pathway Medulloblastoma: What Constitutes Low-risk and How Low Can One Go?

February 27, 2023

The definition of low-risk WNT-pathway medulloblastoma may need to be refined in light of recent clinical data and newer biological information.” BUFFALO, NY- February 27, 2023 – A new research... read more